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Abstract
Purpose of review—The purpose of this review is to highlight macrophages as central
mediators of intestinal immune homeostasis and inflammation.
Recent findings—We review recent developments elucidating distinct phenotypic adaptations
in intestinal macrophages that determine their functional role in a microbe-rich environment. The
involvement of intestinal macrophages in the pathogenesis of inflammatory bowel disease is also
discussed.
Summary—Intestinal macrophages represent the largest pool of tissue macrophages in the
human body and a critical interface with the enteric microbiota. In normal physiology, luminal
microbes breach the intestinal epithelial barrier and gain access to the lamina propria. Bacteria are
efficiently phagocytosed by macrophages strategically located underneath the epithelium. The
importance of functional adaptations of macrophages to perform their role in this unique
environment is best illustrated by failure of these mechanisms during the development of chronic
inflammatory bowel diseases. Compared with monocytes or macrophages from any other organ,
intestinal macrophages express different phenotypic markers, efficiently eradicate intracellular
bacteria, but do not mount potent inflammatory responses. Converging human genetic and
functional findings suggest that dysregulation of macrophage-specific immune responses against
an otherwise harmless enteric microbiota are key factors in the pathogenesis of inflammatory
bowel disease.
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Introduction
The innate immune system contributes to the functional integrity of the intestinal mucosa in
health and disease through monitoring of luminal contents, particularly the enteric
microbiota. Key participants in intestinal innate immune defenses are macrophages. Innate
responses are rapid and directed toward conserved patterns of carbohydrate and lipid
structures on infectious agents [pathogen-associated molecular patterns, or (PAMPs)]
recognized by germ line-encoded pattern recognition receptors, toll-like receptors (TLRs)
and nod-like receptors (NLRs) [1]. Engagement of these receptors stimulates signaling
cascades that include nuclear factor-κB, serine/threonine protein kinase (AKT)/
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phosphoinositide-3’-kinase, and mitogen-activated protein kinase pathways [2]. Mutations
in TLRs and NLRs have been associated with inflammatory bowel disease (IBD),
suggesting that this innate immune detection system is key for regulating mucosal
homeostasis [3].
The intestinal innate immune system is in a default state of hyporesponsiveness. Intestinal
macrophages show attenuated proliferation and chemotactic activity in response to microbial
ligands and cytokines/chemokines despite possessing the molecular mechanisms to elaborate
strong phagocytic and bactericidal responses [4]. However, in IBD, following an
inflammatory signal, circulating monocytes migrate to the intestinal mucosa and, unlike
resident macrophages, are capable of a rapid response to luminal microbial triggers [5].
Current views on macrophage development and biology
A common myeloid progenitor cell gives rise to monocytes, which are released from the
bone marrow into the bloodstream. These peripheral blood monocytes migrate to tissues
under the steady state or in response to inflammation. Innate and adaptive signals can then
influence macrophage physiology, and these alterations allow macrophages to participate in
homeostatic processes, such as tissue remodeling, wound healing, and host defense.
Macrophages also have remarkable plasticity that allows them to efficiently respond to
environmental signals and change their functional characteristics.
Macrophages have been somewhat simplistically classified as M1 [high interleukin (IL)-12
and low IL-10 producing] macrophages and M2 macrophages (low IL-12 and high IL-10
producing). M1 or classically activated macrophages develop during cell-mediated immune
responses requiring both interferon (IFN)-γ and tumor necrosis factor (TNF). Classically
activated macrophages form an integral component of host defense through production of
inflammatory cytokines such as IL-1, IL-6, IL-12, and IL-23 [6]. Phenotypically, M1
macrophages are identified by the expression of inducible nitric oxide synthase, C-C motif
chemokine 15 (CCL15) and 20 (CCL20), γ-interferon-induced monokine 9 (CXCL9) and 10
(CXCL10) [6]. M1 macrophages are essential for eradication of intracellular
microorganisms [7•]. However, they are also mediators of pathology that occurs during
chronic inflammatory disorders, including IBD.
M2 or alternatively activated macrophages represent a wide array of macrophage
phenotypes [6]. This spectrum includes macrophages with wound healing and regulatory
properties [6]. In response to injury, early increases in IL-4 and/or IL-13 rapidly convert
resident macrophages into a population of cells programmed to promote wound healing
through production of extracellular matrix [8]. Regulatory macrophages that arise during
innate or adaptive immune responses, under the influence of IL-10 and transforming growth
factor (TGF)-β, dampen the immune response and limit inflammation [6]. Production of
IL-10, TGF-β, PGE2, and the ability to suppress IL-12 production are hallmarks of
regulatory macrophages [9]. Phenotypically, M2 macrophages are identified by the
expression of arginase 1, chitinase-like protein that can bind to extracellular matrix, and
found in inflammatory zone 1 [10].
Microbial recognition and eradication by macrophages
Macrophages are essential for the phagocytosis and clearance of enteric bacteria that breach
the intestinal epithelial barrier [11]. Autophagy and phagolysosomal function have emerged
as central components of the macrophage machinery to eradicate intracellular bacteria [12].
Indeed, the importance of microbicidal pathways in the pathogenesis of IBD is highlighted
by the discovery that synonymous single nucleotide polymorphisms in the autophagocytic
genes ATG16L1 and IRGM and the phagosomal gene NCF4 are associated with enhanced
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risk for IBD [1,12]. Moreover, the Crohn’s disease susceptibility gene N has recently been
linked to autophagy [13•]. Autophagy, directly translated as ‘self-eating’, is a process
whereby cells digest their own organelles or cytoplasm, allowing survival during periods of
nutrient deprivation. Importantly, autophagy is required to protect against bacteria that
invade cells, and recent functional analyses suggest that Crohn’s disease-associated
autophagy mutations may impair the ability of cells to eradicate intracellular bacteria
[14,15]. Signaling through NLRs and TLRs can lead to autophagosome formation [13•,16].
During autophagy, cytoplasmic material including organelles, protein aggregates, or bacteria
is sequestered into double membrane-bound autophagosomes that subsequently fuse with
endosomes and lysosomes to form autolysosomes, where lysosomal degradation occurs.
Autophagy also has a major role in antigen presentation, with fusion of autophagosomes
with multivesicular major histocompatibility complex (MHC) class II loading compartments
in macrophages [17].
A fundamental question in mucosal immunity is how mucosal innate host defense
distinguishes pathogenic from resident microbes. It is not known how pattern recognition
receptors such as NLRs and TLRs differentiate conserved molecular patterns on pathogenic
and commensal bacteria, nor is it known how this recognition process may be altered in
IBD.
Distinct properties of resident intestinal macrophages
The local intestinal microenvironment substantially influences the differentiation of
macrophages. Intestinal macrophages express high levels of MHC class II and the myeloid
marker aminopeptidase N (CD13), similarly to blood monocytes (Table 1) [18-26].
However, in contrast to their progenitor cells, resident monocytes, intestinal macrophages do
not function as professional antigen-presenting cells (APC) owing to their low cell surface
expression of the costimulatory molecules CD40, CD80, and CD86 [20]. They also lack the
Fc receptors for immunoglobulin A (CD89) and for immunoglobulin G (CD16, CD32, and
CD64) and the complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18).
Similarly, most intestinal macrophages lack the integrin α2β1 (lymphocyte function-
associated antigen-1 and CD11a/CD18) [20,21]. These receptors for the Fc and complement
family members on macrophages mediate cellular activation, secretion of proinflammatory
cytokines (TNF, IL-1β, IL-6, and IL-12) and drive adaptive immune responses. Intestinal
macrophages also lack the triggering receptor expressed on myeloid cells-1 (TREM-1), an
efficient amplifier of acute and chronic inflammatory reactions that is expressed on most
monocytes and macrophages in secondary lymphoid organs [22]. Engagement of TREM-1
on TREM-1-positive macrophages leads to enhanced TNF, IL-1β, and IL-6 secretion.
Upregulation of several cell surface molecules (C40, CD86, and CD32) also prolongs
survival of TREM-1-positive myeloid cells [22].
The selective absence of these receptors on intestinal macrophages has functional
implications in the maintenance of immune homeostasis. Intestinal macrophages under
physiological conditions are refractory to the induction of inflammatory cytokines by
PAMPs, cytokines (e.g., TNF, IFN-γ), and phagocytosis of necrotic cells [4]. This is in sharp
contrast to other tissue macrophages and blood monocytes. Intestinal epithelial cells,
subepithelial myofibroblasts, fibroblasts, lamina propria lymphocytes, and intraepithelial
lymphocytes also produce soluble factors, particularly TGF-β and IL-10, which determine
the functional properties of intestinal macrophages [27,28]. However, these adaptations
made by intestinal macrophages do not impair phagocytic activity. Intestinal macrophages
are highly effective at killing phagocytosed enteric bacteria such as Salmonella typhimurium
and Escherichia coli [21].
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Regulation of intestinal macrophage phenotype and function
The local intestinal milieu shapes the function and phenotype of intestinal macrophages.
Blood monocytes treated with intestinal stromal cell-conditioned media rich in TGF-β
acquire a tolerized state with reduced expression of innate immune receptors and increased
phagocytotic activity, similar to intestinal macrophages. Blocking TGF-β reverses these
effects [21]. Similarly, IL-10, produced under physiological conditions in the intestinal
lamina propria, directly dampens macrophage function and upregulates TGF-β production in
multiple cell types [29]. Interestingly, monocytes cultured in the presence of TGF-β alone or
in combination with IL-10 do not acquire an intestinal macrophage phenotype [22].
However, monocytes cultured with multicellular spheroids of intestinal epithelial cells
acquire an intestinal macrophage phenotype, characterized by reduced CD14 and reduced
lipopolysaccharides-stimulated IL-1β expression [30].
Macrophages also maintain intestinal immune homeostasis through the generation of anergic
and/ or regulatory T cells in the intestine, and fine tuning adaptive immune responses by
altering the Th1/Th2/Th17 balance [31]. Retinoic acid directly influences the development
and effector functions of intestinal macrophages. A population of CD11b+ F4/80+ CD11c−
intestinal macrophages that constitutively produce high levels of IL-10 express high levels
of Aldh1a1 and Aldh1a2, retinol dehydrogenases that convert retinol into retinoic acid, and
induce T-regulatory cells [32,33]. These macrophages convert naïve CD4+ T cells to Foxp3+
T cells in vitro in the presence of exogenous TGF-β via a mechanism dependent on both
IL-10 and Aldh1a1 and Aldh1a2 [33]. Importantly, not all intestinal APCs induce T-
regulatory cells. CD11c+CD11b+ subset of dendritic cells in the lamina propria induces
robust Th17 responses [33]. These studies emphasize the complexity of the intestinal APC
network that differentially regulates mucosal immune responses.
Lessons learned from murine models of experimental colitis
Murine models of experimental colitis have demonstrated the importance of macrophage
regulation for maintaining local tissue homeostasis. Selective disruption of Stat3 leads to
impaired IL-10 signaling in macrophages and consequently leads to the development of
colitis [34]. Similarly, IL-10−/− mice spontaneously develop colitis as a consequence of the
preferential macrophage differentiation into proinflammatory subsets that produce large
amounts of IL-12 and IL-23 [35]. Depletion of macrophages in IL-10−/− mice prevents the
development of colitis [35].
Of the inflammatory genes induced in macrophages, IL-23 has been strongly implicated in
the pathogenesis of murine and human IBD [3]. IL-23 promotes a distinct CD4+ T-cell
phenotype characterized by the production of the cytokine IL-17, denoted Th17 cells. IL-23
enhances Th17 function and survival by acting on differentiated Th17 cells that express the
IL-23 receptor. Indeed, IFN-γ, the signature Th1 cytokine induced by IL-12, and IL-10 were
both recently shown to inhibit IL-23 in lamina propria macrophages [36•]. As an illustration
of the functional adaptation of intestinal macrophages to their local environment, murine
colonic macrophages produce large amounts of IL-10 after encountering the enteric
microbiota [35]. In the context of adaptive immune responses, IFN-γ has been considered to
be a proinflammatory cytokine, driving Th1 responses. However, the enteric microbiota
transiently induces IFN-γ expression in the colon of wild type germfree mice colonized with
the enteric microbiota, which in turn attenuated IL-23 in macrophages, suggesting that local
macrophage-specific regulatory check points are vital in maintaining immune homeostasis
[36•].
The importance of intestinal macrophages in maintaining adaptive immune homeostasis was
recently highlighted in studies showing that IL-10 secreted from resident intestinal
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macrophages acts in a paracrine manner on regulatory T (Treg) cells to maintain Foxp3
expression [37•]. These Foxp3 expressing Treg cells have been shown to suppress the
activity of Th1 and Th17 cells in inflamed tissues [1].
Intestinal macrophages in human inflammatory bowel disease
Intestinal inflammation in the human IBDs, Crohn’s disease and ulcerative colitis, results
from an inappropriately directed inflammatory response to the enteric microbiota in a
genetically susceptible host. Genome wide association studies have identified IBD
susceptibility genes that affect barrier function and innate and adaptive immune responses in
the intestine. Genetic variants that confer Crohn’s disease risk highlight the importance of
innate immunity, including NOD2, NCX5, IRGM, and ATG16L1 [3].
In patients with active IBD, macrophage numbers are increased in inflamed intestinal
mucosa [1]. Many of these macrophages display a different phenotypic and functional
profile than under homeostatic conditions. Macrophages in the inflamed intestine express
functional T cell costimulatory molecules such as CD40, CD80, and CD86 [18].
Furthermore, subsets of intestinal macrophages express TLR2, TLR4, CD89, and TREM-1
at the site of intestinal inflammation [19]. Similarly, a high proportion of the macrophages
from patients with IBD express CD14 [20,24]. CD14 expressing macrophages (CD14+)
infiltrating the mucosa in IBD produce larger amounts of IL-12, IL-23, and TNF compared
with intestinal macrophages from healthy controls. These CD14+ macrophages produce
IFN-γ that further triggers abnormal macrophage differentiation with an IL-23-hyper-
producing phenotype [35]. In an inflammatory milieu, the close proximity of subepithelial
macrophages to the intestinal microbiota results in an excessive activation of the mucosal
immune system [35]. CD14+ intestinal macrophages from Crohn’s disease patients respond
vigorously to in-vitro microbial stimulation with production of abundant TNF, IL-12, and
IL-23, compared with CD14− intestinal macrophages [24]. CD14+ intestinal macrophages
also express TREM-1. TREM-1 triggers the synthesis and secretion of inflammatory factors
including IL-1β, monocyte chemotactic protein-1 (MCP-1), IL-6, and IL-8 [5]. Macrophages
are also the main source of TNF during the pathogenesis of IBD. The striking clinical
benefit of TNF-targeted monoclonal antibody therapies may be attributed to the cell-
depleting effects, including the removal of TNF membrane bound expressing macrophages
[38].
An impaired ability to eradicate intracellular pathogens by macrophages in IBD may also be
secondary to their inability to secrete proinflammatory cytokines in response to bacteria or
TLR agonists. Provocatively, it has been speculated that, despite normal levels and stability
of cytokine mRNA, intracellular levels of TNF are abnormally low in macrophages from
Crohn’s disease patients. Coupled with reduced secretion, these findings indicate that
accelerated intracellular defects in genes encoding proteins involved in vesicle trafficking
may result in an abnormal proportion of cytokines being routed to lysosomes and degraded
rather than being released through the normal secretory pathway [7•].
The concept that macrophages from patients with IBD display distinct functional
characteristics was further supported by studies demonstrating mutations in genes encoding
the IL-10 receptor (IL-10R) subunit proteins IIL10RA and IL10RB in patients with early-
onset enterocolitis [39••]. Increased secretion of TNF, macrophage inflammatory protein-1
(MIP1)α, MIP1β, MCP-1 and chemokine (C-C motif) ligand 5 (RANTES), and failure to
downregulate inflammatory cytokine expression by IL-10 in peripheral blood monocytes
from patients who were deficient in IL-10R subunit proteins, again demonstrate altered
macrophage responses that may underlie IBD pathogenesis. Interestingly, in this study,
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remission was achieved in one patient following allogeneic bone marrow transplantation,
correcting the IL-10 signaling defect in macrophages [39••].
Conclusion
Until recently, research on the pathogenesis of IBD has focused on effector mechanisms of
the adaptive immune system. The relevance of macrophages in IBD is highlighted by their
functions as gatekeepers, driving (not bridging) adaptive immune responses to either
tolerance or initiation of inflammation. Detailed mechanisms of how intestinal macrophages
functionally differentiate and participate in the pathogenesis of IBD may suggest specific
strategies that target induction of macrophage specific regulatory responses and prevent
chronic inflammation.
Vital to the development of such therapies is an intricate knowledge about the monocyte/
macrophage lineage relationships, differential homing capacities, and the effects of the local
cytokine milieu on macrophage function and phenotype, and the plasticity of intestinal
macrophage subsets.
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Table 1
Distinct phenotypic and functional properties of intestinal macrophages and blood monocytes
Phenotype
Intestinal macrophages Blood monocytes
CD14, CD25 − +
TREM-1, CD69 − +
CD89, CD16 − +
CD80, CD86, CD40 − +
CCR5, CXCR4 − +
TGF-βR1, TGF-βRII + +
CD25, CD123 − +
HLA-DR, CD33, CD13 + +
Function
 Phagocytosis + +
 Killing + +
 Antigen presentation − +
 Chemotaxis − +
 Costimulation − +
 Cytokine production − +
This is a summary of functional and phenotypic differences between intestinal macrophages and blood monocytes. Data was collected from
references [18-26]. HLA-DR, human leukocyte antigen-DR; TGF, transforming growth factor; TREM-1, triggering receptor expressed on myeloid
cells-1.
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